Ratti Ram Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ratti Ram Sharma has a total of 393 co-authors. Here are the top co-authors by number of shared publications:
Rekha Hans
Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
15 shared publicationsNeelam Marwaha
Department of Transfusion Medicine PGIMER Chandigarh India
14 shared publications- Ashish Jain
Department of Transfusion Medicine Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh India
11 shared publications - Rekha Hans
Department of Transfusion Medicine Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh India
7 shared publications Divjot Singh Lamba
Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
5 shared publications- José Mauro Kutner
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
5 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4) , 106538
Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies
- 18 September 2026
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (4) , 106538
Open AccessComparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies
- 12 May 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (8) , e70388
Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks
Background: The aim was to enhance access to autologous stem cell transplant (ASCT) for high‐risk neuroblastoma in a public hospital in a lower‐middle‐income country, while ensuring safety. Methods: Data from a single center were analyzed in this ambispective, observational study spanning 12 years (2012–2023). The adaptations included performing ASCT in isolation rooms within the general ward, storing stem cells at 2°C–6°C without cryopreservation for 7 days, utilizing plerixafor for stem cell mobilization, no central lines, minimizing venipunctures for sampling, no antibacterial/antifungal/antiviral prophylaxis, administering pegylated‐G‐CSF on Day +4, avoiding platelet transfusion for asymptomatic thrombocytopenia, prednisolone for preventing engraftment syndrome, and early discharge upon rising white cell count and monocytosis. Results: Seventy‐three patients were treated on the backbone of the high‐risk neuroblastoma study‐1 of SIOP‐Europe (SIOPEN). The median age was 38 months. Sixty‐six (90.4%) patients had Stage 4 disease. A regimen of busulfan+melphalan was administered to 62 (84.9%) patients. Median CD34 cell count and stem cell viability were 5.2 × 10 6 /kg and 91.5%. The median hospital stay was 20 days. At discharge, the median absolute neutrophil and platelet counts were 0.60 × 10 9 /L and 19 × 10 9 /L. After 2017, there was a reduction in the number of aphereses ( p < 0.001), blood transfusions ( p = 0.003), amphotericin ( p = 0.012), and venipunctures ( p = 0.045). Forty (54.8%) patients died; relapse: 33 (82.5%); progressive disease: five (12.5%); and treatment‐related mortality: two (5%). There was no case of engraftment failure. The median follow‐up for surviving patients was 55.3 months. Five‐year overall survival (OS) and event‐free survival (EFS) were 34.6% ± 6.6% and 27% ± 5.8%. Survival was comparable to our historical cohort of 28 patients treated without ASCT (4‐year EFS: 29.3%; 4‐year OS: 29.3%). Conclusion: In our cohort, the incorporation of ASCT into multimodality therapy was feasible with resource‐adapted strategies; however, this did not translate into a meaningful improvement in survival outcomes when compared with our historical non‐transplant cohort.
- 12 May 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (8) , e70388
Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low‐ and Lower‐Middle‐Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks
Background: The aim was to enhance access to autologous stem cell transplant (ASCT) for high‐risk neuroblastoma in a public hospital in a lower‐middle‐income country, while ensuring safety. Methods: Data from a single center were analyzed in this ambispective, observational study spanning 12 years (2012–2023). The adaptations included performing ASCT in isolation rooms within the general ward, storing stem cells at 2°C–6°C without cryopreservation for 7 days, utilizing plerixafor for stem cell mobilization, no central lines, minimizing venipunctures for sampling, no antibacterial/antifungal/antiviral prophylaxis, administering pegylated‐G‐CSF on Day +4, avoiding platelet transfusion for asymptomatic thrombocytopenia, prednisolone for preventing engraftment syndrome, and early discharge upon rising white cell count and monocytosis. Results: Seventy‐three patients were treated on the backbone of the high‐risk neuroblastoma study‐1 of SIOP‐Europe (SIOPEN). The median age was 38 months. Sixty‐six (90.4%) patients had Stage 4 disease. A regimen of busulfan+melphalan was administered to 62 (84.9%) patients. Median CD34 cell count and stem cell viability were 5.2 × 10 6 /kg and 91.5%. The median hospital stay was 20 days. At discharge, the median absolute neutrophil and platelet counts were 0.60 × 10 9 /L and 19 × 10 9 /L. After 2017, there was a reduction in the number of aphereses ( p < 0.001), blood transfusions ( p = 0.003), amphotericin ( p = 0.012), and venipunctures ( p = 0.045). Forty (54.8%) patients died; relapse: 33 (82.5%); progressive disease: five (12.5%); and treatment‐related mortality: two (5%). There was no case of engraftment failure. The median follow‐up for surviving patients was 55.3 months. Five‐year overall survival (OS) and event‐free survival (EFS) were 34.6% ± 6.6% and 27% ± 5.8%. Survival was comparable to our historical cohort of 28 patients treated without ASCT (4‐year EFS: 29.3%; 4‐year OS: 29.3%). Conclusion: In our cohort, the incorporation of ASCT into multimodality therapy was feasible with resource‐adapted strategies; however, this did not translate into a meaningful improvement in survival outcomes when compared with our historical non‐transplant cohort.
- 11 March 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (6) , 848-860
Indication of transfusion of blood components in paediatric and neonatal patients in India: Real‐world multicentre data
Background and Objectives: Globally, there is high variability in paediatric transfusion practices. As per the World Health Organization (WHO), the majority of transfusions in low‐income countries are administered to children under 5 years. This study aimed to characterize the epidemiology and indications for blood component transfusions among neonatal and paediatric patients across India. Materials and Methods: A prospective longitudinal multicentre study was conducted over 6 months (April–September 2022). Standardized data sheets captured age, gender, diagnosis, transfusion indication, component type and first versus repeat transfusion status for all paediatric requests. Results: Twenty‐three medical institutions (combined 32,759 beds) participated in the study. Among 396,092 total blood component requests, 52,658 (13.2%) were for paediatric patients. Most were male (60.1%), aged 5–12 years (26.4%), and 42.7% required >1 transfusion. Red cell components were the most frequently requested (68%), followed by platelets (17.5%) and plasma (12.3%). Medical indications accounted for 67.6% requests, followed by 30.3% surgical indications. Haematology (48%), oncology (17.1%) and infections (10.5%) were the most common medical indications; however, cardiac surgeries (44.2%) and gastrointestinal surgeries (30%) were the most common surgical indications. Haemoglobinopathies (21.4%) were overall the most common indication for the transfusions reported. Conclusion: Paediatric patients accounted for over 13% of all transfusion requests, predominantly for red cells and medical indications (mainly haemoglobinopathy). This represents the first large‐scale epidemiological assessment of paediatric transfusion indications in India and establishes foundational evidence to guide understanding of blood utilization trends in children as well as indicate priority research areas for the future.
- 11 March 2026
- Published by Wiley in Vox Sanguinis
- Vol. 121 (6) , 848-860
Indication of transfusion of blood components in paediatric and neonatal patients in India: Real‐world multicentre data
Background and Objectives: Globally, there is high variability in paediatric transfusion practices. As per the World Health Organization (WHO), the majority of transfusions in low‐income countries are administered to children under 5 years. This study aimed to characterize the epidemiology and indications for blood component transfusions among neonatal and paediatric patients across India. Materials and Methods: A prospective longitudinal multicentre study was conducted over 6 months (April–September 2022). Standardized data sheets captured age, gender, diagnosis, transfusion indication, component type and first versus repeat transfusion status for all paediatric requests. Results: Twenty‐three medical institutions (combined 32,759 beds) participated in the study. Among 396,092 total blood component requests, 52,658 (13.2%) were for paediatric patients. Most were male (60.1%), aged 5–12 years (26.4%), and 42.7% required >1 transfusion. Red cell components were the most frequently requested (68%), followed by platelets (17.5%) and plasma (12.3%). Medical indications accounted for 67.6% requests, followed by 30.3% surgical indications. Haematology (48%), oncology (17.1%) and infections (10.5%) were the most common medical indications; however, cardiac surgeries (44.2%) and gastrointestinal surgeries (30%) were the most common surgical indications. Haemoglobinopathies (21.4%) were overall the most common indication for the transfusions reported. Conclusion: Paediatric patients accounted for over 13% of all transfusion requests, predominantly for red cells and medical indications (mainly haemoglobinopathy). This represents the first large‐scale epidemiological assessment of paediatric transfusion indications in India and establishes foundational evidence to guide understanding of blood utilization trends in children as well as indicate priority research areas for the future.
- 24 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (1)
Comparative Efficacy of Standard‐Volume Plasma Exchange Versus High‐Volume Plasma Exchange in Patients With Acute‐on‐Chronic Liver Failure
High‐volume therapeutic plasma exchange (HV‐TPE) is an established treatment modality in acute liver failure; however, its role in acute‐on‐chronic liver failure (ACLF) and its comparative efficacy versus standard‐volume TPE (SV‐TPE) remain unclear. This single‐center, prospective, randomized pilot study conducted over 2 years (2021–2023) compared the efficacy of HV‐TPE and SV‐TPE in patients with ACLF. Twenty‐two consecutive patients with ACLF Grade I and II without prospects for liver transplantation were enrolled; 11 patients underwent HV‐TPE, and 11 underwent SV‐TPE. In addition to tolerability, the effects of both TPE modalities on coagulation parameters, biochemical indices, cytokine levels (IL‐6, IL‐10, and TNF‐α), and clinical severity scores—including the Asia Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) score, Maddrey discriminant function (MDF), Model for End‐Stage Liver Disease (MELD), and Child‐Turcotte‐Pugh (CTP) score—were assessed before and after therapy. Length of hospital stay and 30‐day and 90‐day mortality were also compared. Both HV‐TPE and SV‐TPE resulted in significant improvement in coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR), along with significant reductions in serum total and conjugated bilirubin, alkaline phosphatase, total protein, and serum ammonia ( p < 0.05). Significant improvement in serum urea ( p = 0.004), serum creatinine ( p = 0.004), and serum lactate ( p = 0.007) was observed only in the HV‐TPE group. Clinical severity scores (AARC, MDF, MELD, and CTP) improved significantly in both groups ( p < 0.05). There were no significant differences between the groups in 30‐day mortality (27% vs. 27%, p = 1.00), 90‐day mortality (36% vs. 45%, p = 0.40), or changes in cytokine levels. Procedure‐related adverse events were infrequent and comparable between HV‐TPE (6.8%) and SV‐TPE (5.7%). In conclusion, both HV‐TPE and SV‐TPE effectively improved clinical severity scores in patients with ACLF; however, a definitive difference in mortality benefit could not be demonstrated in this study. Trial Registration: CTRI/2019/06/019660 (dated 14 June 2019)
- 24 February 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (1)
Comparative Efficacy of Standard‐Volume Plasma Exchange Versus High‐Volume Plasma Exchange in Patients With Acute‐on‐Chronic Liver Failure
High‐volume therapeutic plasma exchange (HV‐TPE) is an established treatment modality in acute liver failure; however, its role in acute‐on‐chronic liver failure (ACLF) and its comparative efficacy versus standard‐volume TPE (SV‐TPE) remain unclear. This single‐center, prospective, randomized pilot study conducted over 2 years (2021–2023) compared the efficacy of HV‐TPE and SV‐TPE in patients with ACLF. Twenty‐two consecutive patients with ACLF Grade I and II without prospects for liver transplantation were enrolled; 11 patients underwent HV‐TPE, and 11 underwent SV‐TPE. In addition to tolerability, the effects of both TPE modalities on coagulation parameters, biochemical indices, cytokine levels (IL‐6, IL‐10, and TNF‐α), and clinical severity scores—including the Asia Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) score, Maddrey discriminant function (MDF), Model for End‐Stage Liver Disease (MELD), and Child‐Turcotte‐Pugh (CTP) score—were assessed before and after therapy. Length of hospital stay and 30‐day and 90‐day mortality were also compared. Both HV‐TPE and SV‐TPE resulted in significant improvement in coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR), along with significant reductions in serum total and conjugated bilirubin, alkaline phosphatase, total protein, and serum ammonia ( p < 0.05). Significant improvement in serum urea ( p = 0.004), serum creatinine ( p = 0.004), and serum lactate ( p = 0.007) was observed only in the HV‐TPE group. Clinical severity scores (AARC, MDF, MELD, and CTP) improved significantly in both groups ( p < 0.05). There were no significant differences between the groups in 30‐day mortality (27% vs. 27%, p = 1.00), 90‐day mortality (36% vs. 45%, p = 0.40), or changes in cytokine levels. Procedure‐related adverse events were infrequent and comparable between HV‐TPE (6.8%) and SV‐TPE (5.7%). In conclusion, both HV‐TPE and SV‐TPE effectively improved clinical severity scores in patients with ACLF; however, a definitive difference in mortality benefit could not be demonstrated in this study. Trial Registration: CTRI/2019/06/019660 (dated 14 June 2019)
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41340
Normative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from india: the INDIIGo study
The INDIIGo study aimed to establish normative data for serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in adult Indian males, addressing the paucity of data for the South East Asian population. This cross-sectional study included 1271 healthy males aged 20 to 65.9 years from Chandigarh, India, with measurements obtained using the Roche Elecsys electrochemiluminescence immunoassay (ECLIA). Age-specific normative centile curves were generated using the LMS (Lambda, Mu, Sigma) method. Serum IGF-1 levels declined by 30.1 ng/ml per decade (95% CI - 34.9 to - 25.2; p < 0.001) and were negatively associated with lower socioeconomic status (- 5.8 ng/ml per class; p = 0.002), ALT (- 0.6 ng/ml per unit; p < 0.001), and HbA1c (- 8.2 ng/ml per category; p = 0.04). Positive correlations were observed with serum T4 (+ 4.5 ng/ml per unit; p < 0.001) and serum albumin (+ 18.0 ng/ml per g/dL; p = 0.009). IGFBP-3 levels decreased by 447.8 ng/ml per decade (95% CI - 547.6 to - 348.1; p < 0.001), with a significant positive association with serum T4 (+ 60.8 ng/ml per unit; p = 0.025). This study provides age-specific normative data for IGF-1 and IGFBP-3 in Indian males and identifies key factors influencing these biomarkers.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41340
Open AccessNormative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from india: the INDIIGo study
The INDIIGo study aimed to establish normative data for serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in adult Indian males, addressing the paucity of data for the South East Asian population. This cross-sectional study included 1271 healthy males aged 20 to 65.9 years from Chandigarh, India, with measurements obtained using the Roche Elecsys electrochemiluminescence immunoassay (ECLIA). Age-specific normative centile curves were generated using the LMS (Lambda, Mu, Sigma) method. Serum IGF-1 levels declined by 30.1 ng/ml per decade (95% CI - 34.9 to - 25.2; p < 0.001) and were negatively associated with lower socioeconomic status (- 5.8 ng/ml per class; p = 0.002), ALT (- 0.6 ng/ml per unit; p < 0.001), and HbA1c (- 8.2 ng/ml per category; p = 0.04). Positive correlations were observed with serum T4 (+ 4.5 ng/ml per unit; p < 0.001) and serum albumin (+ 18.0 ng/ml per g/dL; p = 0.009). IGFBP-3 levels decreased by 447.8 ng/ml per decade (95% CI - 547.6 to - 348.1; p < 0.001), with a significant positive association with serum T4 (+ 60.8 ng/ml per unit; p = 0.025). This study provides age-specific normative data for IGF-1 and IGFBP-3 in Indian males and identifies key factors influencing these biomarkers.
- 9 October 2025
- Published by Wiley in Transfusion Medicine
- Vol. 36 (2) , 194-198
All blood discard does not amount to blood wastage—A critical technical reappraisal
Background: Blood centres, as part of their routine operations, generate various forms of waste during the collection‐to‐transfusion continuum. However, not all discarded blood components equate to ‘wastage’. Methods: A critical technical appraisal distinguishing blood discard (necessary and regulatory‐compliant) from blood wastage (preventable and avoidable) was done. Results: We propose clear operational definitions and introduce refined metrics such as blood discard rate (BDR), blood wastage rate (BWR) and total discard rate (TDR) to ensure accurate reporting. The concept of ‘all‐cause blood discard’ encompassing both justified discards and true wastage is emphasised. Conclusion: Misinterpretation of data on discarding as wastage by technical personnel, policymakers, media and the public at large can lead to a trust deficit in transfusion services. Adoption of these distinctions and metrics will improve transparency, resource management and public confidence in blood services.
- 9 October 2025
- Published by Wiley in Transfusion Medicine
- Vol. 36 (2) , 194-198
All blood discard does not amount to blood wastage—A critical technical reappraisal
Background: Blood centres, as part of their routine operations, generate various forms of waste during the collection‐to‐transfusion continuum. However, not all discarded blood components equate to ‘wastage’. Methods: A critical technical appraisal distinguishing blood discard (necessary and regulatory‐compliant) from blood wastage (preventable and avoidable) was done. Results: We propose clear operational definitions and introduce refined metrics such as blood discard rate (BDR), blood wastage rate (BWR) and total discard rate (TDR) to ensure accurate reporting. The concept of ‘all‐cause blood discard’ encompassing both justified discards and true wastage is emphasised. Conclusion: Misinterpretation of data on discarding as wastage by technical personnel, policymakers, media and the public at large can lead to a trust deficit in transfusion services. Adoption of these distinctions and metrics will improve transparency, resource management and public confidence in blood services.
- 16 February 2025
- Published by Wiley in Transfusion Medicine
- Vol. 35 (3) , 215-225
Development and validation of an indigenous questionnaire for assessing clinician's knowledge towards transfusion medicine and bedside transfusion practices
Introduction: Due to the non‐availability of formal training during residency for clinicians in transfusion medicine, there is a prevalent knowledge gap for transfusion practices, which leads to increased patient risks and elevated healthcare costs. There is no indigenous questionnaire available, which could be used for knowledge assessment. This study aims to develop and validate an Indigenous questionnaire to assess clinicians' knowledge of transfusion medicine and bedside transfusion practices.Materials and Methods: The questionnaire was designed using a nominal group technique involving subject experts, considering the type of information required, themes, appropriate wording, layout, and presentation. The questionnaire consisted of 25 knowledge‐based questions and 4 general questions. Piloting of the questionnaire was done to check for feasibility, validation, and reliability. Content validity was assessed by six experts using the Content Validity Index (CVI). Reliability was assessed using test–retest and split‐half methods, with a sample of 56 participants. Cronbach's alpha and Kappa statistics were used to measure internal consistency and agreement, respectively.Results: The questionnaire displayed acceptable feasibility with a mean difficulty score of 6.93 on a scale of 1–10, with test–retest responses showing near‐perfect agreement (kappa value 0.8–0.99). All experts gave more than 70% agreement on the relevance of content, with a mean CVI of 85%. Test–retest reliability showed near‐perfect agreement (Kappa 0.8–0.99, p = 0.008) and good internal consistency (Cronbach's α = 0.806). The split‐half method yielded a Cronbach's α of 0.89 and an intraclass correlation coefficient of 0.88 (95% CI 0.57, 0.97, p = 0.001) Construct validity was confirmed through factor analysis.Conclusion: The developed indigenous questionnaire is a reliable and valid tool for assessing the knowledge of clinicians towards transfusion medicine and bedside transfusion practices. The detailed, methodical strategy used to prepare and validate the questionnaire ensures its applicability and relevance in various clinical settings and can be easily adopted by others intending to prepare similar questionnaires. The questionnaire is available with the author and, on demand, may be provided for knowledge assessment.
- 16 February 2025
- Published by Wiley in Transfusion Medicine
- Vol. 35 (3) , 215-225
Development and validation of an indigenous questionnaire for assessing clinician's knowledge towards transfusion medicine and bedside transfusion practices
Introduction: Due to the non‐availability of formal training during residency for clinicians in transfusion medicine, there is a prevalent knowledge gap for transfusion practices, which leads to increased patient risks and elevated healthcare costs. There is no indigenous questionnaire available, which could be used for knowledge assessment. This study aims to develop and validate an Indigenous questionnaire to assess clinicians' knowledge of transfusion medicine and bedside transfusion practices.Materials and Methods: The questionnaire was designed using a nominal group technique involving subject experts, considering the type of information required, themes, appropriate wording, layout, and presentation. The questionnaire consisted of 25 knowledge‐based questions and 4 general questions. Piloting of the questionnaire was done to check for feasibility, validation, and reliability. Content validity was assessed by six experts using the Content Validity Index (CVI). Reliability was assessed using test–retest and split‐half methods, with a sample of 56 participants. Cronbach's alpha and Kappa statistics were used to measure internal consistency and agreement, respectively.Results: The questionnaire displayed acceptable feasibility with a mean difficulty score of 6.93 on a scale of 1–10, with test–retest responses showing near‐perfect agreement (kappa value 0.8–0.99). All experts gave more than 70% agreement on the relevance of content, with a mean CVI of 85%. Test–retest reliability showed near‐perfect agreement (Kappa 0.8–0.99, p = 0.008) and good internal consistency (Cronbach's α = 0.806). The split‐half method yielded a Cronbach's α of 0.89 and an intraclass correlation coefficient of 0.88 (95% CI 0.57, 0.97, p = 0.001) Construct validity was confirmed through factor analysis.Conclusion: The developed indigenous questionnaire is a reliable and valid tool for assessing the knowledge of clinicians towards transfusion medicine and bedside transfusion practices. The detailed, methodical strategy used to prepare and validate the questionnaire ensures its applicability and relevance in various clinical settings and can be easily adopted by others intending to prepare similar questionnaires. The questionnaire is available with the author and, on demand, may be provided for knowledge assessment.
- 16 January 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (4) , 419-427
Transfusion efficacy of leucoreduced packed red blood cells prepared by two different methods: A randomized controlled trial in transfusion‐dependent thalassaemia patients (FUEL trial)
Background and Objectives: Great variations may be observed in the haemoglobin (Hb) content of packed red blood cell (PRBC) units prepared by different methods. This study aimed to assess the Hb increment in thalassaemia major patients transfused with leucoreduced PRBCs (LPRBCs) prepared by two different methods: (i) standard leucoreduced PRBCs (SLPRBCs) and (ii) leucoreduced PRBCs prepared by a new method where leucoreduction of whole blood is done first (NLPRBCs).Materials and Methods: This prospective, randomized, controlled trial included 80 adult thalassaemia major patients who were randomized into two groups of 40 each. Group I patients received SLPRBC and those of Group II received NLPRBC transfusions for 3 months.Results: SLPRBCs had a mean (±SD) volume of 275.50 ± 17.07 mL, while it was 316.46 ± 1.42 mL for NLPRBCs (p < 0.001). The mean Hb content of SLPRBCs was 50.60 ± 5.12 g, while that of NLPRBCs was 56.98 ± 5.92 g (p < 0.001). The mean Hb increment in Group I patients was 2.11 ± 0.89 g/dL, while that of Group II patients was 2.48 ± 0.88 g/dL (p < 0.001). The mean transfusion interval for Group I patients was 20.30 ± 3.75 days, while it was 21.34 ± 5.13 days for Group II patients (p < 0.045). A significant positive correlation was observed between the Hb dose transfused and the Hb increment with both SLPRBC (ρ = 0.4, p < 0.001) and NLPRBC (ρ = 0.19, p = 0.011) transfusions.Conclusion: NLPRBCs had significantly higher Hb content than the SLPRBCs, leading to a better Hb increment post transfusion, which may potentially prolong the transfusion interval in thalassaemia major patients.
- 16 January 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (4) , 419-427
Transfusion efficacy of leucoreduced packed red blood cells prepared by two different methods: A randomized controlled trial in transfusion‐dependent thalassaemia patients (FUEL trial)
Background and Objectives: Great variations may be observed in the haemoglobin (Hb) content of packed red blood cell (PRBC) units prepared by different methods. This study aimed to assess the Hb increment in thalassaemia major patients transfused with leucoreduced PRBCs (LPRBCs) prepared by two different methods: (i) standard leucoreduced PRBCs (SLPRBCs) and (ii) leucoreduced PRBCs prepared by a new method where leucoreduction of whole blood is done first (NLPRBCs).Materials and Methods: This prospective, randomized, controlled trial included 80 adult thalassaemia major patients who were randomized into two groups of 40 each. Group I patients received SLPRBC and those of Group II received NLPRBC transfusions for 3 months.Results: SLPRBCs had a mean (±SD) volume of 275.50 ± 17.07 mL, while it was 316.46 ± 1.42 mL for NLPRBCs (p < 0.001). The mean Hb content of SLPRBCs was 50.60 ± 5.12 g, while that of NLPRBCs was 56.98 ± 5.92 g (p < 0.001). The mean Hb increment in Group I patients was 2.11 ± 0.89 g/dL, while that of Group II patients was 2.48 ± 0.88 g/dL (p < 0.001). The mean transfusion interval for Group I patients was 20.30 ± 3.75 days, while it was 21.34 ± 5.13 days for Group II patients (p < 0.045). A significant positive correlation was observed between the Hb dose transfused and the Hb increment with both SLPRBC (ρ = 0.4, p < 0.001) and NLPRBC (ρ = 0.19, p = 0.011) transfusions.Conclusion: NLPRBCs had significantly higher Hb content than the SLPRBCs, leading to a better Hb increment post transfusion, which may potentially prolong the transfusion interval in thalassaemia major patients.
- 20 November 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (1) , 104039
Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures
- 20 November 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (1) , 104039
Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures
- 22 July 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 63 (5) , 103974
Breast milk induced immune haemolytic disease of newborn due to anti-c: A case report
- 22 July 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 63 (5) , 103974
Breast milk induced immune haemolytic disease of newborn due to anti-c: A case report